Cellular electrophysiological effect of terikalant in the dog heart

P. Biliczki, K. Acsai, L. Virág, László Tálosi, N. Jost, András Biliczki, J. Papp, A. Varró

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The cellular mechanism of action of terikalant, an investigational antiarrhythmic agent known to block the inward rectifier and other potassium currents, has not yet been fully clarified. The aim of the present study was therefore to analyse the in vitro electrophysiological effects of terikalant in canine isolated ventricular muscle and Purkinje fibers by applying the standard microelectrode technique. The effects of terikalant on the duration of action potential at a stimulation cycle length of 1000 ms and on the maximum upstroke velocity of the action potential in right ventricular papillary muscle were examined at 1, 2.5, 10, and 20 μM concentrations. Terikalant significantly prolonged the action potential duration measured both at 50% and 90% of repolarization in concentration-dependent manner. The maximum upstroke velocity of the action potential was unaffected at 1 and 2.5 μM concentrations. However, this parameter was significantly reduced at 10 and 20 μM concentrations of terikalant. In Purkinje fibers terikalant (2.5 μM) also produced a marked action potential lengthening effect. Frequency dependence (cycle length of 300-5000 ms) of the action potential lengthening effect of terikalant was studied at a concentration of 2.5 μM. Prolongation of the duration of action potential occurred in a reverse frequency-dependent manner both in papillary muscle and Purkinje fibers, with a more pronounced frequency-dependence observed in Purkinje fibers. The onset kinetics of the terikalant (10 μM) induced block of the maximum upstroke velocity of the action potential was rapid (0.6±0.1 beat-1, n=6) like that of Class I/B antiarrhythmics, and the offset (recovery) kinetics of the drug (2956±696 ms, n=6) best resembled that of Class I/A antiarrhythmic drugs. It was concluded that terikalant, unlike pure Class III antiarrhythmic drugs, has combined mode of action by lengthening repolarization and blocking the inward sodium current in a use-dependent manner.

Original languageEnglish
Pages (from-to)161-166
Number of pages6
JournalEuropean Journal of Pharmacology
Volume510
Issue number3
DOIs
Publication statusPublished - Mar 14 2005

Fingerprint

Action Potentials
Dogs
Purkinje Fibers
Papillary Muscles
Anti-Arrhythmia Agents
terikalant
Microelectrodes
Canidae
Potassium
Pharmacokinetics
Sodium
Muscles

Keywords

  • Antiarrhythmic action
  • Cellular electrophysiology
  • Multichannel block
  • Terikalant

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Cellular electrophysiological effect of terikalant in the dog heart. / Biliczki, P.; Acsai, K.; Virág, L.; Tálosi, László; Jost, N.; Biliczki, András; Papp, J.; Varró, A.

In: European Journal of Pharmacology, Vol. 510, No. 3, 14.03.2005, p. 161-166.

Research output: Contribution to journalArticle

@article{ca955682215b409285541d5bd49ed917,
title = "Cellular electrophysiological effect of terikalant in the dog heart",
abstract = "The cellular mechanism of action of terikalant, an investigational antiarrhythmic agent known to block the inward rectifier and other potassium currents, has not yet been fully clarified. The aim of the present study was therefore to analyse the in vitro electrophysiological effects of terikalant in canine isolated ventricular muscle and Purkinje fibers by applying the standard microelectrode technique. The effects of terikalant on the duration of action potential at a stimulation cycle length of 1000 ms and on the maximum upstroke velocity of the action potential in right ventricular papillary muscle were examined at 1, 2.5, 10, and 20 μM concentrations. Terikalant significantly prolonged the action potential duration measured both at 50{\%} and 90{\%} of repolarization in concentration-dependent manner. The maximum upstroke velocity of the action potential was unaffected at 1 and 2.5 μM concentrations. However, this parameter was significantly reduced at 10 and 20 μM concentrations of terikalant. In Purkinje fibers terikalant (2.5 μM) also produced a marked action potential lengthening effect. Frequency dependence (cycle length of 300-5000 ms) of the action potential lengthening effect of terikalant was studied at a concentration of 2.5 μM. Prolongation of the duration of action potential occurred in a reverse frequency-dependent manner both in papillary muscle and Purkinje fibers, with a more pronounced frequency-dependence observed in Purkinje fibers. The onset kinetics of the terikalant (10 μM) induced block of the maximum upstroke velocity of the action potential was rapid (0.6±0.1 beat-1, n=6) like that of Class I/B antiarrhythmics, and the offset (recovery) kinetics of the drug (2956±696 ms, n=6) best resembled that of Class I/A antiarrhythmic drugs. It was concluded that terikalant, unlike pure Class III antiarrhythmic drugs, has combined mode of action by lengthening repolarization and blocking the inward sodium current in a use-dependent manner.",
keywords = "Antiarrhythmic action, Cellular electrophysiology, Multichannel block, Terikalant",
author = "P. Biliczki and K. Acsai and L. Vir{\'a}g and L{\'a}szl{\'o} T{\'a}losi and N. Jost and Andr{\'a}s Biliczki and J. Papp and A. Varr{\'o}",
year = "2005",
month = "3",
day = "14",
doi = "10.1016/j.ejphar.2004.12.040",
language = "English",
volume = "510",
pages = "161--166",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Cellular electrophysiological effect of terikalant in the dog heart

AU - Biliczki, P.

AU - Acsai, K.

AU - Virág, L.

AU - Tálosi, László

AU - Jost, N.

AU - Biliczki, András

AU - Papp, J.

AU - Varró, A.

PY - 2005/3/14

Y1 - 2005/3/14

N2 - The cellular mechanism of action of terikalant, an investigational antiarrhythmic agent known to block the inward rectifier and other potassium currents, has not yet been fully clarified. The aim of the present study was therefore to analyse the in vitro electrophysiological effects of terikalant in canine isolated ventricular muscle and Purkinje fibers by applying the standard microelectrode technique. The effects of terikalant on the duration of action potential at a stimulation cycle length of 1000 ms and on the maximum upstroke velocity of the action potential in right ventricular papillary muscle were examined at 1, 2.5, 10, and 20 μM concentrations. Terikalant significantly prolonged the action potential duration measured both at 50% and 90% of repolarization in concentration-dependent manner. The maximum upstroke velocity of the action potential was unaffected at 1 and 2.5 μM concentrations. However, this parameter was significantly reduced at 10 and 20 μM concentrations of terikalant. In Purkinje fibers terikalant (2.5 μM) also produced a marked action potential lengthening effect. Frequency dependence (cycle length of 300-5000 ms) of the action potential lengthening effect of terikalant was studied at a concentration of 2.5 μM. Prolongation of the duration of action potential occurred in a reverse frequency-dependent manner both in papillary muscle and Purkinje fibers, with a more pronounced frequency-dependence observed in Purkinje fibers. The onset kinetics of the terikalant (10 μM) induced block of the maximum upstroke velocity of the action potential was rapid (0.6±0.1 beat-1, n=6) like that of Class I/B antiarrhythmics, and the offset (recovery) kinetics of the drug (2956±696 ms, n=6) best resembled that of Class I/A antiarrhythmic drugs. It was concluded that terikalant, unlike pure Class III antiarrhythmic drugs, has combined mode of action by lengthening repolarization and blocking the inward sodium current in a use-dependent manner.

AB - The cellular mechanism of action of terikalant, an investigational antiarrhythmic agent known to block the inward rectifier and other potassium currents, has not yet been fully clarified. The aim of the present study was therefore to analyse the in vitro electrophysiological effects of terikalant in canine isolated ventricular muscle and Purkinje fibers by applying the standard microelectrode technique. The effects of terikalant on the duration of action potential at a stimulation cycle length of 1000 ms and on the maximum upstroke velocity of the action potential in right ventricular papillary muscle were examined at 1, 2.5, 10, and 20 μM concentrations. Terikalant significantly prolonged the action potential duration measured both at 50% and 90% of repolarization in concentration-dependent manner. The maximum upstroke velocity of the action potential was unaffected at 1 and 2.5 μM concentrations. However, this parameter was significantly reduced at 10 and 20 μM concentrations of terikalant. In Purkinje fibers terikalant (2.5 μM) also produced a marked action potential lengthening effect. Frequency dependence (cycle length of 300-5000 ms) of the action potential lengthening effect of terikalant was studied at a concentration of 2.5 μM. Prolongation of the duration of action potential occurred in a reverse frequency-dependent manner both in papillary muscle and Purkinje fibers, with a more pronounced frequency-dependence observed in Purkinje fibers. The onset kinetics of the terikalant (10 μM) induced block of the maximum upstroke velocity of the action potential was rapid (0.6±0.1 beat-1, n=6) like that of Class I/B antiarrhythmics, and the offset (recovery) kinetics of the drug (2956±696 ms, n=6) best resembled that of Class I/A antiarrhythmic drugs. It was concluded that terikalant, unlike pure Class III antiarrhythmic drugs, has combined mode of action by lengthening repolarization and blocking the inward sodium current in a use-dependent manner.

KW - Antiarrhythmic action

KW - Cellular electrophysiology

KW - Multichannel block

KW - Terikalant

UR - http://www.scopus.com/inward/record.url?scp=14844286497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14844286497&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2004.12.040

DO - 10.1016/j.ejphar.2004.12.040

M3 - Article

VL - 510

SP - 161

EP - 166

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 3

ER -